2025
Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes
How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsCardiovascular risk factorsEssential thrombocythemiaMyeloproliferative neoplasmsPolycythemia veraThrombotic outcomesThrombotic riskRisk factorsDiagnosis of hematological malignanciesMyeloproliferative neoplasm subtypeIncreased risk of deathType 2 diabetes mellitusMyeloproliferative neoplasms diagnosisRetrospective cohort analysisSex-matched controlsManaging cardiovascular risk factorsAssociated with survivalImprove patient morbidityRisk of deathMF patientsHematologic malignanciesMPN diagnosisPatient morbidityDana-FarberArterial/venous thrombosis
2023
Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms
Bale S, Kim C, How J, Wazir M, Weeks L, Stahl M, Luskin M, DeAngelo D, Lindsley C, Kim A, Mullally A, Marneth A. Mutations in the RNA Splicing Factors U2AF1 and SRSF2 are Context-Dependent in Myeloproliferative Neoplasms. Blood 2023, 142: 1788. DOI: 10.1182/blood-2023-178657.Peer-Reviewed Original ResearchVariant allele frequencySRSF2 mutationsCALR mutationsMyeloproliferative neoplasmsU2AF1 mutationsPathogenic mutationsSplicing factor mutationsCo-mutationsGene mutationsMPN phenotypic driver mutationsPolymerase chain reactionDriver mutationsMyeloproliferative neoplasm driver mutationsSplicing factor genes mutationsCD34-positive bone marrow cellsPositive bone marrow cellsPhenotypic driver mutationsSpliceosome gene mutationsNegative myeloproliferative neoplasmsComprehensive molecular profilingMyeloproliferative neoplasm patientsHematopoietic growth factorsBone marrow cellsSplicing factor U2AF1Pathogenic mutation(sCardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes
How J, Leiva O, Marneth A, Kamaz B, Kim C, Weeks L, Wazir M, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood 2023, 142: 4568. DOI: 10.1182/blood-2023-179324.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsEssential thrombocythemiaVariant allele fractionMyeloproliferative neoplasmsPolycythemia veraAcute myeloid leukemiaHistory of atherosclerotic diseaseMF patientsCV-RFCardiovascular risk factorsRisk of deathOverall survivalRisk factorsMPN diagnosisLeukemia progressionArterial thrombosisGenomic profilingHazard ratioAssociated with increased risk of deathAssociated with adverse outcomesAssociated with higher risk of deathAtherosclerotic diseaseAssociated with increased riskHigher risk of deathAssociated with higher riskTP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms
Rolles B, De Oliveira Filho C, Keating J, Luskin M, DeAngelo D, Lindsley C, Kim A, Hem J, Kim C, Weeks L, Wazir M, How J, Marneth A, Liu Y, Aryee M, Tsai H, Stahl M, Mullally A. TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms. Blood 2023, 142: 3160. DOI: 10.1182/blood-2023-185024.Peer-Reviewed Original ResearchMyeloproliferative neoplasms diagnosisLoss of heterozygosityVariant allele fractionTP53 mutation detectionSecondary AMLTP53 mutationsMyeloproliferative neoplasm subtypeMyeloproliferative neoplasm patientsMyeloproliferative neoplasmsOverall survivalEssential thrombocythemiaCourse of diseasePolycythemia veraDriver mutationsBlast phase myeloproliferative neoplasmsChronic phase myeloproliferative neoplasmsContext of myeloproliferative neoplasmsMyeloproliferative neoplasm driver mutationsNext-generation sequencingDetect TP53 mutationsDiagnosis to detectionPost-ET/PV myelofibrosisTP53-mutant patientsTP53-mutated patientsMutation detection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply